Atai Life Sciences N.V.
ATAI
$1.47
$0.053.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -271.09% | -92.11% | 59.97% | 77.26% | 73.60% |
| Total Depreciation and Amortization | 48.28% | 28.78% | 45.92% | 94.80% | 89.88% |
| Total Amortization of Deferred Charges | 38.81% | 5.71% | 29.61% | 81.69% | 183.21% |
| Total Other Non-Cash Items | 244.17% | 284.89% | -154.33% | -214.26% | -202.16% |
| Change in Net Operating Assets | -223.18% | -421.22% | 75.83% | -167.77% | 323.96% |
| Cash from Operations | 2.00% | 13.55% | 22.57% | 15.76% | 19.48% |
| Capital Expenditure | 97.68% | 97.96% | 99.06% | 102.11% | 66.49% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 200.00% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 211.84% | 81.91% | -113.54% | -139.63% | 38.90% |
| Cash from Investing | 211.03% | 87.78% | -113.94% | -140.19% | 38.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 137.78% | 21.21% | -94.06% | -99.73% | -96.75% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 98.12% | -654.01% | -359.62% | -649.34% | -649.34% |
| Cash from Financing | 164.32% | -297.18% | -142.89% | -141.04% | -140.20% |
| Foreign Exchange rate Adjustments | 91.53% | 118.00% | -29.41% | 97.31% | 116.83% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 87.96% | 52.26% | -287.43% | -345.55% | 15.19% |